Resonance Speci, a company in the Specialty Chemicals industry, reported revenue of ₹34 crore and net profit of ₹8.47 crore for the September 2026 quarter.
Resonance Speci. (BSE: RESONANCE) closed at ₹262.50 on 20 Nov 2026, up 172.8% over the past year. Its market capitalisation is ₹303 crore and it trades at 14.2 times earnings.
Incorporated in 1989, Resonance Specialties Ltd manufactures Pyridine, Picoline, Cynopyridine and derivatives of the same
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.